Business ❯ Pharmaceuticals ❯ Manufacturing

Investment

Eli Lilly Job Creation AstraZeneca Expansion Astrazeneca Sanofi Research and Development Supply chain Tariffs Merck

Lilly Launches $4.5 Billion Indiana Buildout With Opening of First Genetic-Medicine Plant

A planned API complex by 2027 will make medicines for obesity and diabetes to bolster U.S. supply.

AbbVie to Build $1.4 Billion Injectable-Medicines Campus in Durham, N.C.

UCB Picks Georgia’s Rowen for $2 Billion Biologics Campus

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

AstraZeneca Pledges $2 Billion to Expand Maryland Biomanufacturing, Add 2,600 Jobs

AstraZeneca Invests $2 Billion to Expand Maryland Biologics and Build New Clinical Site

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

Merck Breaks Ground on $3 Billion Virginia Plant in $70 Billion U.S. Expansion

AstraZeneca Breaks Ground on $4.5 Billion Virginia Plant With Expanded Cancer and Obesity Drug Production

Eli Lilly Chooses Houston for $6.5 Billion Plant to Produce APIs for Orforglipron and Other Drugs

Eli Lilly Picks Virginia for $5 Billion Bioconjugate Plant, First of Four New U.S. Sites

AbbVie to Build $195 Million API Facility in North Chicago

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030

Sanofi Announces $20 Billion U.S. Investment to Expand Manufacturing and R&D

Roche Commits $700M to North Carolina Biologics Facility as Part of $50B U.S. Expansion

Novartis Confirms $23 Billion U.S. Investment with Major Expansion Plans

Novartis Announces $23 Billion U.S. Expansion with New Plants and R&D Hub

Eli Lilly Announces $27 Billion Investment in U.S. Manufacturing Expansion

Eli Lilly Announces $3 Billion Wisconsin Manufacturing Expansion